Expertise in
41
conditions

Dr. Gerald Y. Ho

Rheumatology
5451 La Palma Ave, 
La Palma, CA 
Accepting New Patients
Offers Telehealth
Referral required
Before you request
Expertise in
41
conditions
5451 La Palma Ave, 
La Palma, CA 

Overview

Gerald Ho is a Rheumatologist practicing medicine in La Palma, California.

Dr. Ho is highly rated in 41 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Osteoporosis, Postmenopausal Osteoporosis, and Sjogren Syndrome.

Dr. Ho is board certified in American Board Of Rheumatology. He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 6 clinical trials. Dr. Ho is currently accepting new patients.

Specialties

Rheumatology

Licenses

Internal Medicine in CA

Board Certifications

American Board Of Rheumatology

Fellowships

UCLA - Sepulveda Veterans Affairs Med Ctr , Rheumatology , 1991 - 1993

Hospital Affiliations

Garfield Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Nippon Life
  • INSURANCE PLAN
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Arthritis And Osteoporosis Medical Cente
5451 La Palma Ave, La Palma, CA 90623

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-sMTS for the Treatment of Postmenopausal Women With Osteoporosis (the wearABLe Study)
A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-sMTS for the Treatment of Postmenopausal Women With Osteoporosis (the wearABLe Study)
Enrollment Status: Completed
Publish Date: February 15, 2023
Intervention Type: Combination product
Study Drugs: Abaloparatide solid microstructured transdermal system, Abaloparatide subcutaneous
Study Phase: Phase 3
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
Enrollment Status: Terminated
Publish Date: April 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multi-center, Randomized, Double-blinded, Placebo-controlled, Multiple-ascending-dose Study of Brentuximab Vedotin in Adults With Active Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blinded, Placebo-controlled, Multiple-ascending-dose Study of Brentuximab Vedotin in Adults With Active Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: June 11, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

2 Total Publications

Spontaneous Development of Immune-Mediated Necrotizing Myopathy (IMNM) After Chronic Use of Statins: A Case Report.
Spontaneous Development of Immune-Mediated Necrotizing Myopathy (IMNM) After Chronic Use of Statins: A Case Report.
Journal: Cureus
Published: July 21, 2023
Similar Doctors
Expertise in
13
conditions
Dr. Daniel E. Furst
Rheumatology
Expertise in
13
conditions
Dr. Daniel E. Furst
Rheumatology
Referral may be required
Before you request

Daniel Furst MD A Professional Corp.

575 E Hardy St Ste 321, 
Inglewood, CA 
 (19.1 miles away)
818-561-9989
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Furst is a Rheumatologist practicing medicine in Inglewood, California. Dr. Furst is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Systemic Sclerosis (SSc), Scleroderma, Rheumatoid Arthritis (RA), and Arthritis. Dr. Furst is currently accepting new patients.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required
2020 Santa Monica Boulevard, Suite 540, 
Santa Monica, CA 
 (28.2 miles away)
310-582-6350
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tanaz Kermani is a Rheumatologist practicing medicine in Santa Monica, California. Dr. Kermani is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Temporal Arteritis, Giant Cell Arteritis (GCA), Vasculitis, and Takayasu Arteritis. Dr. Kermani is currently accepting new patients.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required
Before you request

Cedars-Sinai Rheumatology-Los Angeles

8723 Alden Dr Ste 250, 
Los Angeles, CA 
 (24.7 miles away)
Languages Spoken:
English
See accepted insurances

Daniel Wallace is a Rheumatologist practicing medicine in Los Angeles, California. Dr. Wallace is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Sjogren Syndrome, and Rheumatoid Arthritis (RA).

Frequently Asked Questions about Dr. Gerald Y. Ho

How do I make an appointment with Dr. Gerald Y. Ho?

You can book an appointment with Dr. Gerald Y. Ho by calling their office at 714-670-1340. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Gerald Y. Ho a top-rated expert for Rheumatoid Arthritis (RA)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Gerald Y. Ho is classified as an Distinguished expert for Rheumatoid Arthritis (RA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Gerald Y. Ho specialize in?

While Dr. Gerald Y. Ho is a Rheumatology, they have specific expertise in Rheumatoid Arthritis (RA), Osteoporosis, and Postmenopausal Osteoporosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Gerald Y. Ho participate in research or clinical trials?

Yes. Dr. Gerald Y. Ho has published 2 articles and abstracts on conditions like Rheumatoid Arthritis (RA). You can view a list of Dr. Gerald Y. Ho's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Gerald Y. Ho accept my insurance?

Dr. Gerald Y. Ho accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 714-670-1340 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ho's expertise for a condition
ConditionClose
    View All 20 Distinguished Conditions
    View All 21 Advanced Conditions
    View All 31 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile